• NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew sold 8,494 ordinary shares on June 18 at USD 0.66.
• Holdings fell to 157,941 ordinary shares following the sale.
• Andrew also acquired 23,695 ordinary shares on June 17 via an equity award transaction.
• He reported 82,422 restricted share units after the June 17 vesting-related transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002089237-26-000006), on June 22, 2026, and is solely responsible for the information contained therein.